ArticleObstetrics and gynecology international2013
Mesh exposure and associated risk factors in women undergoing transvaginal prolapse repair with mesh.
Article in Obstetrics and gynecology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Long-term outcomes of a randomized controlled trial comparing trans-obturator vaginal mesh with native tissue repair in the treatment of anterior vaginal wall prolapse.International urogynecology journal · 2020Trial
- Toward a Future Where Diabetes No Longer Limits Mesh Surgery.International urogynecology journal · 2026Article
- Patient-Reported Long-Term Outcomes of Laparoscopic Sacrocolpopexy.International urogynecology journal · 2026Article
- Association of Preoperative Inflammatory and Immune Markers with Mesh Exposure After Transvaginal Mesh Surgery for Pelvic Organ Prolapse.International urogynecology journal · 2026Article
- Editorial: A Perspective from the Editor.International urogynecology journal · 2026Article
- Dysregulated inflammatory response to urogynecologic meshes in women with diabetes and its implications.American journal of obstetrics and gynecology · 2024Article
- Anterior-apical Transvaginal Mesh (Calistar-S) for Treatment of Advanced Urogenital Prolapse: Surgical and Functional Outcomes at 1 Year.International urogynecology journal · 2024Article
- Characterization of vaginal immune response to a polypropylene mesh: Diabetic vs. normoglycemic conditions.Acta biomaterialia · 2022Article
- Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application.Frontiers in cell and developmental biology · 2020Review
- Mesh-related complications of laparoscopic sacrocolpopexy.International urogynecology journal · 2019Article
- The role of synthetic and biologic materials in the treatment of pelvic organ prolapse.Clinics in colon and rectal surgery · 2014Review
- Synthetic Graft Augmentation in Vaginal Prolapse Surgery: Long-Term Objective and Subjective Outcomes.Journal of minimally invasive gynecologyObservational
- The Role of the Surgeon on Outcomes of Vaginal Prolapse Surgery With Mesh.Female pelvic medicine & reconstructive surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Objective. To determine frequency, rate, and risk factors associated with mesh exposure in women undergoing transvaginal prolapse repair with polypropylene mesh. Methods. Retrospective chart review was performed for all women who underwent Prolift Pelvic Floor Repair System (Gynecare, Somerville, NJ) between September 2005 and September 2008. Multivariable logistic regression was performed to identify risk factors for mesh exposure. Results. 201 women underwent Prolift. Mesh exposure occurred in 12% (24/201). Median time to mesh exposure was 62 days (range: 10-372). When mesh was placed in the anterior compartment, the frequency of mesh exposure was higher than that when mesh was placed in the posterior compartment (8.7% versus 2.9%, P = 0.04). Independent risk factors for mesh exposure were diabetes (AOR = 7.7, 95% CI 1.6-37.6; P = 0.01) and surgeon (AOR = 7.3, 95% CI 1.9-28.6; P = 0.004). Conclusion. Women with diabetes have a 7-fold increased risk for mesh exposure after transvaginal prolapse repair using Prolift. The variable rate of mesh exposure amongst surgeons may be related to technique. The anterior vaginal wall may be at higher risk of mesh exposure as compared to the posterior vaginal wall.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.